This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Taysse, L. Articles by Breton, P. Search for Related Content PubMed PubMed Citation Articles by Taysse, L. Articles by Breton, P. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Botox Social Bookmarking                         What's this?

Induction of Acute Lung Injury after Intranasal Administration of Toxin Botulinum A Complex

Centre d’Etudes du Bouchet (Defense Research Center), BP No. 3, 91710 Vert le Petit, France

Correspondence: Address correspondence to: L. Taysse, Centre d’Etudes du Bouchet, BP No. 3, Vert le Petit, 91710, France; e-mail:laurent.taysse{at}dga.defense.gouv.fr

	Abstract

TOP Abstract Introduction Materials and Methods Results Discussion References

 
The inhalation of aerozolized botulinum toxin may represent a potential significant hazard to both military and civilian personnel. Since the lung is the primary target organ for inhaled toxin, the investigation reported herein was conducted to examine lung function in mice exposed to botulinum toxin A complex by intranasal route. Data includes lethality, symptomatology, measurement of respiratory function (minute ventilation, respiratory frequency, and tidal volume), and histopathology of the lungs. The clinical signs of intoxication are similar to those observed in foodborne botulism. Plethysmography revealed severe impairment of all respiratory parameters tested from 7 hours postexposure. Severe lung lesions, possibly secondary to the intoxication, were observed in mice who survived 14 days after the toxin challenge. These included intra-alveolar hemorrhage and interstitial edema. Mice immunized by the pentavalent (ABCDE) toxoid were protected against the neurotoxin (4 LD50) as revealed by the decrease of lethality and severity of nervous signs of intoxication, but not against histopathological changes in the lungs. These effects are nonspecific and require further experiments in order to specify the relationships between the pathology and the inflammatory process in the lung due to mediators such as cytokines, and possibly permanent physiological sequelae.

Key Words: Botulinum neurotoxin • histopathology • lungs • plethysmography • vaccin • toxicity • inflammatory process

	Introduction

TOP Abstract Introduction Materials and Methods Results Discussion References

 
Clostridium botulinum produces 7 different neurotoxins, designated A to G, which are extremely potent protein toxins. Toxin types A, B, E, and F are mainly implicated in human diseases. Foodborne botulism accounts for most botulinum intoxication cases. However, exposure to toxins A to E through aerosols or in contaminated water is seriously considered a potential threat as a warfare or bioterrorist agent (Franz et al., 1993).

Botulinum toxins inhibit the release of acetylcholine (Simpson, 1986) at neuromuscular junctions, resulting in flaccid muscle paralysis. Respiratory failure due to the paralysis of respiratory muscles is the most serious complication, resulting in death (Davis, 1993; Franz et al., 1993). These toxins also interfere with transmission at cholinergic parasympathetic terminals, producing autonomic symptoms: dry mouth and eyes, urinary retention, fluctuations of blood pressure, and impairment of autonomic control of heart rate. Recovery is slow, and the most common complaints are easy fatigue and dyspnea, although objective measurements of pulmonary function are usually normal. Many prophylactic and therapeutic countermeasures against botulism have been investigated since 1940. A new generation of botulinum vaccine is now under study: various laboratories are focused on the development of synthetic (Atassi et al., 1996; Atassi and Oshima, 1999) or recombinant vaccines against botulinum neurotoxins (Clayton et al., 1995; Gelzleichter et al., 1999; Clayton and Middlebrook, 2000). In this context, a pentavalent botulinum toxoid (PBT) directed against serotypes A to E (Siegel, 1988) is proposed to immunize specific at-risk populations, i.e., scientists in contact with botulinum toxins, and armed forces, which may be subjected to weaponized forms of the toxin. Inhalation appears to be the most likely route of exposure for the toxin if used as a terrorist weapon or warfare agent. However, this kind of poisoning seems to be particular. In testing the efficacy of vaccination against inhaled ricin in mouse (DaSilva et al., 2003), some remaining lesions in lungs were noticed even though the animals were well protected from death.

The present study was conducted in order to examine whether botulinum toxin A complex, administered by intranasal route in mice, was able to induce lung alterations even if the animals were protected against the neurotoxic effects.

	Materials and Methods

TOP Abstract Introduction Materials and Methods Results Discussion References

 
Animals
Six-week-old male BALB/C mice, weighing 20–25 g at the time of exposure, were obtained from Charles River (Saint Aubain-les-Elbeuf, France). The animals were acclimatized to the laboratory conditions for at least 1 week before the experiment. They were housed 10 per cage under a 12:12-hour light/dark cycle (0600–1800 hours lights on). Food and water were available ad libitum.

The principles of Laboratory Animal Care were followed in all experiments. The experimental design of the study was approved by our institute’s Ethical Commitee.

Isolation of the Toxin A Complex
Type A neurotoxin was produced in cultures as BoNT/A-complex, a protein containing the type A neurotoxin and 6–7 nontoxic proteins. These nontoxic proteins have hemagglu-tinating activity and stabilize the neurotoxin. BoNT/A complex has been isolated from the bacterial Clostridium botulinum type A NCTC 2916 strain, according to a previously described extraction protocol (Malizio et al., 2000).

The culture was incubated for 24 hours at 37°C in anaerobic condition without any agitation in glass bottles, each containing 0.5 L TGY medium. The TGY is a broth nutritive medium containing glucose and yeast extract to support the growth of Clostridium botulinum.

It was then acidified by H₂SO₄ to pH 3.5. A heavy precipitate settled in 2–3 hours. It was collected by centrifugation (12.000 x g, 20 minutes, 4°C), washed twice with water, homogenized, and extracted with 0.05 M Na₂HPO₄/NaH₂PO₄ buffer pH 6. The solution was saturated with ammonium sulfate (35.1 g/100 ml) and stored at 4°C for 3 hours. The new precipitate was recovered by centrifugation (12,000 x g, 20 minutes, 4°C), dissolved in 0.05 M citrate buffer pH 5.5, and then dialyzed against 1 L of the same buffer for at least 18 hours at 4°C. The molecular cutoff of the dialysis tubing is 1 kDa. The solution was then centrifuged (12.000 x g, 20 minutes, 4°C) to remove insoluble material. The supernatant was loaded on a Q Sepharose Fast Flow column (25 ml, flow rate 5 ml/minute) equilibrated previously with 0.05 M citrate buffer (pH 5.5). The column was washed with the same buffer, and the collected toxin solution was saturated with solid ammonium sulfate (35.1 g/100 ml) and stored at 4°C for 3 hours. Then, the precipitate was processed as above and the supernatant was applied on a Sephacryl S-300 HR column (300 ml, flow rate 1 ml/minute), equilibrated, and then eluted with a 0.05 M citrate, 0.15 M NaCl buffer at pH 5.5. The second isolated peak contains the toxin. The toxin solution was concentrated at 20 µg/ml by ultrafiltration (Centripep Amicon 50,000 MWCO).

Toxic Activity
Mice were slightly anesthetized by an intraperitoneal injection of 100 mg/kg of ketamine. They were injected with the toxin solution into 1 nostril, using an automatic pipette (Gilson Pipetman P200, Rainin Instrument CO, Woburn, MA) fitted with a gel-loading pipette tip (Fisher Scientific, Pittsburgh, PA). The injected volume was equal to 1 µl of botulinum toxin solution per gram of body weight. Five groups of 10 mice were exposed to the botulinum complex A (from 10 to 30 ng/kg intranasal) and observed for mortality/clinical signs for up to 14 days postexposure. A probit analysis program was used to generate the dose–response curve and estimate the LD50.

Toxic Activity in Immunized Animals
The animals were divided into 2 groups: one (control; n = 10) receiving a saline solution as pretreatment and a second (vaccine group; n = 10) receiving a vaccine according the protocol shown in Figure 1. The vaccine was a Botulinum pentavalent (ABCDE) toxoid purchased from the Michigan Department of Public Health (MDPH). The product contains formalin-inactivated botulinum toxins of types A, B, C, D, and E, absorbed into aluminium phosphate. Each vial contains 0.022% formaldehyde and 1:10,000 thimerosal as preservative. Thirty days after the first injection of vaccine, animals received 4LD50 of BoNT/A complex in the same conditions as previously described for the evaluation of toxic activity.

View larger version (25K): [in this window] [in a new window]   Figure 1 Protocol followed to immunise mouse with PBT vaccine (all injections were subcutaneous at a volume of 0.2 ml).

Antibody Titration
Immune antibody response was determined by an enzyme-linked immunosorbent assay (ELISA) in 6-well microtiter plates. Preparation of inactivated toxin was obtained from a sample of purified botulinum toxin A inactivated by formalin (1%) and NaCl (0.85%). After a 2-day incubation at 4°C, the solution was dialyzed against 1 L of phosphate salt buffer pH 7.2 at 4°C for 1 day. Primary mouse antitoxin antibodies were detected with peroxidase-labeled anti-mouse IgG secondary antibody reagents (Interchim, France). The specificity of IgG was determined by the manufacture against the purified immunoglobulin. Inactivated botulinum toxin A was adsorbed onto the wells of the plates by incubation (100 ng/100 µl) overnight at room temperature. Plasma samples (1:10 dilution) were incubated in the coated plates to select toxin-specific antibodies. Dilutions were made in PBS containing bovine serum albumin (1% w/v) and Tween 20 (0.5% v/v). Each antibody layer, primary and secondary, was incubated in the plates for 1 hour at 37°C. After that, the plates were washed 3 times with PBS containing 0.05% Tween 20. Bound immunoglobulins were detected using anti-mouse immunoglobulins labeled with horseradish peroxidase enzyme (HRPO) (Interchim, France). When incubated with ABTS (azinobis-ethylbenzothiozoline sulphonic acid; Sigma) in 0.2 M citrate/phosphate buffer pH 4.3 containing H₂O₂ (0.01% v/v), a colored product was formed. The amount of mouse anti-toxin IgG was determined spectrophotometrically by the measurement of the intensity of color at 414 nm with a microplate reader. Nonspecific absorbance was eliminated by subtracting the absorbance recorded from the pooled sera of naive mice. Results were expressed as optical density (O.D.).

Signs and Symptoms
The clinical observation started at the end of the slight anesthesia status. Signs and symptoms were recorded at 2, 5, 7, 24, and 48 hours, and 7 and 15 days after toxin exposure. They included behavioral changes, locomotor activity, breathing rate, and ophthalmic status. For each of them, 3 levels of severity were defined and the symptoms were classified according to the scoring scale given in Table 1.

Respiratory function was measured during 15-minute periods. Recordings were made the day before the exposure (control values) and, together with clinical observations, at 2, 5, 7, and 24 hours following the toxin challenge.

Histology
Fourteen days after toxin exposure, all surviving animals were humanely euthanized, and the lungs were removed. The tissues were fixed in formaldehyde (10%) at room temperature for a period of not less than 48 hours. After this time, each lung was trimmed to produce representative blocks from both left and right lobes, sections (6 µm) were cut from paraffin blocks and routinely stained with Harris’s hematoxylin and eosin. Histological sections were examined without knowledge of treatment, by a pathologist.

Data Analysis
Significant differences in the clinical signs scores from the control values (before exposure) on the corresponding times for each experimental group were analysed by the nonparametric paired Wilcoxon’s t-test. For each respiratory parameter in each experimental group, statistical differences between basal values and those measured at 2 hours, 5 hours, 7 hours, and 24 hours were assessed using the same test.

	Results

TOP Abstract Introduction Materials and Methods Results Discussion References

 
Symptoms and Lethality
The LD50 was found to be 21.1 ng/kg with a confidence interval at 95% (13.9–32.5 ng/kg; Table 3). Up to 17.3 ng/kg, symptoms generally developed 48 hours after nasal deposition (Table 2). The onset and the severity of the symptoms together with the number of affected animals were dose-dependent. Symptoms (score 1, Table 1) typically included prostration, inactivity, piloerection, polypsnea, a refusal to eat or drink, and ptosis in some cases. The animals remained in this state until death or, more often, returned to normal behavior on day 15. Doses between 17.3 and 30 ng/kg induced more severe dose-dependent signs of intoxication (score 2). Neurologic symptoms first concerned weakness of the cranial muscles progressively generalizing to the whole musculature and affecting locomotion. Neurophtalmological signs, anorexia, and labored respiration (bradypnea) were observed 48 hours after exposure. In severe cases (4LD50) the incubation period was as short as 7 hours.

View larger version (76K): [in this window] [in a new window]   Figure 3 Respiratory parameters, minute ventilation (A), tidal volume (B) and respiratory frequency (C) recording after 4 LD50 botulinum toxin administered by intranasal exposition. For each parameter, bars give the mean ± SE of 10 values at different times after the toxin deposit, except at T +24 hr where only 4 animals survived in control group. Statistical differences were assessed between control and vaccine groups by the Wilcoxon’s non parametric test. *P < 0.05.

Symptoms in Protected Animals
One week after the first injection, antitoxin IgG was detected in plasma, the mean optical density (O.D.) being 0.23 ± 0.12 (Figure 2) at day 15. one week after the first booster, the amount of IgG was enhanced by 260% (0.61 ± 0.26). At day 30, (1 day prior to botulinum neurotoxin challenge) the levels of O.D. had increased again to reach 1.4 ± 0.35.

View larger version (12K): [in this window] [in a new window]   Figure 2 Immune antibody response of mouse after treatment with PBT vaccine. Each point is the mean ± SE of ten values of a group of mice immunised with PBT vaccine.

Histology
During autopsy, visual observation revealed a significant inflammation of lung tissue. Examination of PBT-treated mice at day 14 (Figure 5) and unprotected mice that survived (Figure 6) 24 hours after exposure to toxins showed severe histopathological alterations in the lung, compared to healthy animals (Figure 4). Staining with hematoxylin and eosin revealed a thickening of the alveolar septa and perivascular areas together with a generalized spreading interstitial edema and a moderate intra-alveola/intrabronchiola hemorrhage (Figures 5 and 6). Signs of inflammation were noticed in the interstitial tissues with a marked proliferation of the macrophage cells.

View larger version (180K): [in this window] [in a new window]   Figure 4–6 Light micrographs of lung sections stained with hematoxylin and eosin from, 4. healthy animal; 5. mice treated with vaccine and exposed to botulinum toxin (4 LD50); 6. mice exposed to botulinum toxin and not vaccined (4 LD50). Inflammatory cell recruitment, substantial intersticial oedema was observed in microphotographs B and C (original magnification x40).

	Discussion

TOP Abstract Introduction Materials and Methods Results Discussion References

Some animal experiments examined botulism by inhalation (Franz et al., 1993; Gelzleichter et al., 1999; DaSilva et al., 2003). Rhesus monkeys exposed to an approximately 2000-mouse intraperitoneal lethal dose (50 ng/kg) of aerosolized liquid botulinum toxin (Franz et al., 1993) died 2–4 days after exposure to the toxin. Clinical signs included intermittent ptosis, severe weakness, mouth breathing, serous nasal discharge, rales, salivation, and dyspnea before death. No histological change directly attributable to botulinum toxin was observed. However, mild-to-moderate subacute submucosal tracheitis, possibly secondary to the intoxication, was noticed in 2 of the 4 animals that died (Franz et al., 1993). In our experiment, signs of intoxication were rather similar. They first included piloerection and ptosis 7 hours after toxin exposure. This last symptom was generally attributed to the symmetrical cranial nerve impairment affecting the bulbar musculature resulting from a toxin-induced blockade of the voluntary motor and autonomic cholinergic junctions (Habermann and Dreyer, 1986). Then, severe muscular weakness, dysphagia, and dyspnea were observed in all the mice 24 hours after challenge. Death occurred 7 hours to 1 week after the toxin deposit.

Ventilatory failure and dyspnea due to the paralysis of respiratory muscles are usually responsible for death in botulinum intoxication in humans (Tacket and Rogawski, 1989) and characterise the ultimate symptom in the progress of pathology. Apart from clinical observations, no data were available for the evaluation of respiratory function after inhalation of botulinum toxins. In our experiment, plethysmo-graphic evaluation revealed a significant modification 7 hours after toxin exposure, although clinical examination was usually normal. Twenty-four hours after the intoxication, all pneumophysiological parameters measured (minute ventilation, tidal volume, and frequency) were affected. At this state of the disease, dyspnea was clinically observed and a few animals were already dead. These observations are in good accord with the fact that botulinum toxin A produces a more severe disease in terms of skeletal muscle weakness and need for ventilatory support.

Numerous studies have documented the ability of pentavalent botulinum toxoid (PBT) to induce protection against lethal effects (Gelzleichter et al., 1999). Our data suggest that, with regard to intranasal exposure, the antitoxin titer was sufficient to prevent all signs of intoxication when animals received 4LD50. No modifications of respiratory parameters were recorded in the PBT-treated group, suggesting that neurotransmission (mainly cholinergic) was fully protected. In this context, the recording of pneumophysiological parameters may be useful to assess immunotherapy against botulism as shown in many infectious models (De Hennezel et al., 2001).

It seems that many inhaled toxins could induce inflammatory-immune processes (Paddle, 2003) as a patho-physiological lung defense response. In the present experiment, animals exposed to the BoNT/A complex showed pulmonary histological changes with edematous lung injury. These data, together with the fact that lung pathology was also present in animals protected against neurological expression of botulism by vaccine, could suggest inflammatory processes independent of the toxic agent. Inhaled toxicants frequently induce an inflammatory response in the lungs. Such alterations were particulary observed after ricin (Rippy et al., 1991) or abrin (Griffiths et al., 1995a, 1995b) inhalation. It is well known that a number of cytokines, such as tumor necrosis factor (TNF), are produced in response to many stimulatory agents (Van Deuren et al., 1992). The mediators are capable of interacting synergistically to modulate the intensity of the inflammatory response. As an example, adult respiratory distress syndrome (ARDS), characterized in part by severe acute hypoxemia and pulmonary edema, shows high levels of several cytokines, including TNF, measured in bronchoalveolar lavage fluid (Suter et al., 1992). TNF potentiates adhesion and activation of endothelial cell monolayers of polymorphonuclear neutrophils (PMN), increasing the monolayer permeability (Gibbs et al., 1990). TNF may also directly increase pulmonary vascular permeability (Horvath et al., 1988). A previous study showed that ricin induces the release of TNF and IL-1β by human peripheral blood mononuclear cells (Licastro et al., 1993). More recently, it was shown that ricin transcriptionally activated a large number of inflammatory mediators (DaSilva et al., 2003). This activation correlated with the increase in total protein content in bronchoalveolar lavages, suggesting increased permeability of the air–blood barrier and cytotoxicity. However, further investigation is required to determine whether there is a direct cytotoxic action of the toxin on lung cells or the recognition of the toxin as a foreign agent and the initiation of an immune-defense response. From the present investigation, a strong inflammatory response in the lungs seems to be of great consideration in botulinum toxin inhalation. A recent publication that investigated the toxicity caused by intranasal administration of Staphylococcal Enterotoxin B also reported pulmonary edema and bronchopneumonia (Savransky et al., 2003). Our histological data correlates well with this assumption.

In conclusion, the present data indicates that botulinum toxin administered by the intranasal route induces lung lesions in addition to its neurotoxic action. This pneumopathology corroborates the previous findings with ricin and staphylococal enterotoxin B. However, the relationship between the histological and physiological data needs further investigations in order to determine whether the observed effects are mainly due to the BoNT/A complex or are also shared by free BoNT/A. Futhermore, the long-term influence on pulmonary function during recovery must also be investigated.

	Acknowledgments

 
We thank Mr. Guillot, Mr. Desforges, Mr. Morio, and Mr. Cocher for their technical assistance. This research was supported by grants from the Defense Ministery DGA/STTC/SH.

	References

TOP Abstract Introduction Materials and Methods Results Discussion References

 

• Atassi, MZ, Dolimbbek, BZ, Hayakari, M, Middlebrook, JL, Whitney, B, & Oshima, M. (1996). Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855–1296 with antitoxin antibodies from three host species. J Prot Chem, 15, 691-700[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Atassi, MZ, & Oshima, M. (1999). Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol, 19, 219-60[Web of Science][Medline] [Order article via Infotrieve]
• Clayton, MA, Clayton, JM, Brown, DR, & Middlebrook, J. (1995). Protective vaccination with a recombinant fragment of clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun, 63, 2738-42[Abstract]
• Clayton, J, & Middlebrook, JL. (2000). Vaccination of mice withe DNA encoding a large fragment of botulinum neurotoxin serotype A. Vaccine, 18, 1855-62[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• DaSilva, L, Cote, D, Roy, C, Martinez, M, Duniho, S, Pitt, ML, Downey, T, & Dertzbaugh, M. (2003). Pulmonary gene expression profiling of inhaled ricin. Toxicon, 41, 813-22[Medline] [Order article via Infotrieve]
• Davis, LE. (1993). Botulinum toxin. From poison to medicine. West J Med, 158, 25-9[Web of Science][Medline] [Order article via Infotrieve]
• De Hennezel, L, Debarre, S, Ramisse, F, Delamanche, S, Harf, A, Alonso, JM, & Calvet, JH. (2001). Plethysmography for the assessment of pneumococcal pneumonia and passive immunotherapy in a mouse model. Eur Respi J, 17, 94-9[CrossRef]
• Franz, DR, Pitt, LM, Clayton, MA, Hanes, MA, & Rose, KJ. In Das Gupta (Ed.). (1993). Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. Botulinum and Tetanus Neurotoxins. NY
• Gelzleichter, TR, Myers, MA, Menton, RG, Niemuth, NA, Matthews, MC, & Langford, MJ. (1999). Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model. J Appl Toxicol, 19, S35-8[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gibbs, L, Lai, L, & Malik, AB. (1990). Tumour necrosis factor enhances the neutropil-dependent increase in endothelial permeability. J Cell Physiol, 145, 496-500[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Griffiths, GD, Lindsay, AC, Allenby, AC, Bailey, JW, Rice, P, & Upshall, DG. (1995a). Protection against inhalation toxicity of ricin and abrin by immunisation. Hum Exp Toxicol, 14, 155-64[Abstract/Free Full Text]
• Griffiths, GD, Rice, P, Allenby, AC, Bailey, SC, & Upshall, DG. (1995b). Inhalation toxicology and histopathology of ricin and abrin toxins. Inhal toxicol, 7, 269-88[CrossRef][Web of Science]
• Habermann, E, & Dreyer, F. (1986). Clostridial neurotoxins: handling and action at the cellular and molecular level. Cuv Top Microbiol Immunol, 129, 93-179
• Holzer, E. (1962). Botulism caused by inhalation. Med Klin, 41, 1735-40
• Horvath, CJ, Ferro, TJ, Jesmok, G, & Malik, AB. (1988). Recombinant tumour necrosis factor increases pulmonary vascular permeability independant of neutrophils. Proc Nat Acad Sci USA, 58, 9219-23
• Licastro, F, Morini, MC, Bolognesi, A, & Stirpe, F. (1993). Ricin induces the production of tumour necrosis factor- and interleuke-1β by human peripheral-blood mononuclear cells. Biochem J, 294, 517-20[Web of Science][Medline] [Order article via Infotrieve]
• Malizio, CJ, Goodnough, MC, & Johnson, EA. In Holst (Ed.). (2000). Purification of clostridium botulinum Type A neurotoxin. Bacterial Toxins, 145, 27-40, Methods in Molecular Biology[CrossRef]
• Paddle, BM. (2003). Therapy and prophylaxis of inhaled biological toxins. J Appl Toxicol, 23, 139-70[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rippy, MK, Riera, VR, Hewetson, JF, Creasia, DA, & Zack, PM. (1991). Immunization with ricin toxoid prevents death and reduces lung injury after aerosol challenge with ricin. Meeting abstract from Society of Toxicologic Pathologists: Monterey
• Savransky, V, Rostapshov, V, Pinelis, D, Polotsky, Y, Korolev, S, Komisar, J, & Federing, K. (2003). Murine lethal toxic shock caused by intranasal administration of Staphylococcal enterotoxin B. Toxicol Pathol, 31, 373-8[Abstract/Free Full Text]
• Siegel, LS. (1988). Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol, 26, 2351-6[Abstract/Free Full Text]
• Simpson, LL. (1986). The origin, structure, and pharmacological activity of botulinum toxin. Pharm Exp Ther, 33, 155-88
• Suter, PM, Suter, S, Girardin, E, Roux-Lombard, P, Grau, GE, & Dayer, JM. (1992). High broncho-alveolar levels of tumor necrosis factor and its inhibitor, interleukine-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, sepsis. Am Rev Respir Dis, 145, 1016-22[Web of Science][Medline] [Order article via Infotrieve]
• Tacket, CO, & Rogawski, MA. In Simpson, LL (Ed.). (1989). Botulism. Botulinum Neurotoxin and Tetanus Toxin (pp.351-78, Academic Press
• Van Deuren, M, Dofferhoff, ASM, & Van Der Meer, JWM. (1992). Cytokines and the response to infection. J Pathol, 168, 340-56

Toxicologic Pathology, Vol. 33, No. 3, 336-342 (2005)
DOI: 10.1080/01926230590922884


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Taysse, L. Articles by Breton, P. Search for Related Content PubMed PubMed Citation Articles by Taysse, L. Articles by Breton, P. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Botox Social Bookmarking                         What's this?